RKDA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.6M
+12.2%
1.4M
+31.2%
1.1M
+22.1%
901.0K
-30.8%
1.3M
Cost of Revenue
760.0K
-6.4%
812.0K
+16.0%
700.0K
-1.3%
709.0K
-19.8%
884.0K
Gross Profit
859.0K
+36.1%
631.0K
+57.8%
400.0K
+108.3%
192.0K
-54.1%
418.0K
Operating Expenses
1.7M
+50.7%
1.1M
-4.4%
1.2M
-24.8%
1.6M
-0.2%
1.6M
R&D
0
0
0
0
0
SG&A
1.7M
+50.7%
1.1M
-4.4%
1.2M
-24.8%
1.6M
-0.2%
1.6M
Operating Income
-839000
-69.2%
-496000
+36.3%
-779000
+43.3%
-1375000
-19.4%
-1152000
EBITDA
-839000
-69.2%
-496000
+35.7%
-771000
+43.8%
-1373000
-19.4%
-1150000
Net Income
1.8M
+128.0%
-6266000
-42.9%
-4385000
-228.2%
-1336000
-256.1%
856.0K
EPS (Basic)
$0.29
+113.9%
$-2.09
+0.9%
$-2.11
-117.5%
$-0.97
-254.0%
$0.63
EPS (Diluted)
$0.29
+113.9%
$-2.09
+0.9%
$-2.11
-115.3%
$-0.98
-258.1%
$0.62
Shares (Diluted)
6.1M
+102.7%
3.0M
+43.7%
2.1M
+52.4%
1.4M
-0.3%
1.4M
Arcadia Biosciences (RKDA) — Financials